Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia

Benjamin Cocanougher, Umut Aypar, Amber McDonald, Linda Hasadsri, Michael J. Bennett, W Edward Jr. Highsmith, Kristin D'Aco

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Galactosemia is a metabolic disorder caused by mutations in the GALT gene [1,2]. We encountered a patient heterozygous for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]. Reminiscent of patients with the S135L mutation, our patient had loss of GALT enzyme activity in erythrocytes but a very mild clinical phenotype [3-8]. We performed splicing experiments and computational structural analyses to investigate the role of the novel S222N variant. Alamut software data predicted loss of splicing enhancers for the S222N and S135L mutations [9,10]. A cDNA library was generated from our patient's RNA to investigate for splicing errors, but no change in transcript length was seen [3]. In silico structural analysis was performed to investigate enzyme stability and attempt to understand the mechanism of the atypical galactosemia phenotype. Stability results are publicly available in the GALT Protein Database 2.0 [11-14]. Animations were created to give the reader a dynamic view of the enzyme structure and mutation locations. Protein database files and python scripts are included for further investigation.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalData in Brief
Volume3
DOIs
StatePublished - Jun 1 2015

Fingerprint

structural analysis
experiment
software

ASJC Scopus subject areas

  • General
  • Education

Cite this

Cocanougher, B., Aypar, U., McDonald, A., Hasadsri, L., Bennett, M. J., Highsmith, W. E. J., & D'Aco, K. (2015). Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia. Data in Brief, 3, 34-39. https://doi.org/10.1016/j.dib.2015.01.001

Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia. / Cocanougher, Benjamin; Aypar, Umut; McDonald, Amber; Hasadsri, Linda; Bennett, Michael J.; Highsmith, W Edward Jr.; D'Aco, Kristin.

In: Data in Brief, Vol. 3, 01.06.2015, p. 34-39.

Research output: Contribution to journalArticle

Cocanougher, Benjamin ; Aypar, Umut ; McDonald, Amber ; Hasadsri, Linda ; Bennett, Michael J. ; Highsmith, W Edward Jr. ; D'Aco, Kristin. / Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia. In: Data in Brief. 2015 ; Vol. 3. pp. 34-39.
@article{a65dffc8acb9486885538513c7ba7fa5,
title = "Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia",
abstract = "Galactosemia is a metabolic disorder caused by mutations in the GALT gene [1,2]. We encountered a patient heterozygous for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]. Reminiscent of patients with the S135L mutation, our patient had loss of GALT enzyme activity in erythrocytes but a very mild clinical phenotype [3-8]. We performed splicing experiments and computational structural analyses to investigate the role of the novel S222N variant. Alamut software data predicted loss of splicing enhancers for the S222N and S135L mutations [9,10]. A cDNA library was generated from our patient's RNA to investigate for splicing errors, but no change in transcript length was seen [3]. In silico structural analysis was performed to investigate enzyme stability and attempt to understand the mechanism of the atypical galactosemia phenotype. Stability results are publicly available in the GALT Protein Database 2.0 [11-14]. Animations were created to give the reader a dynamic view of the enzyme structure and mutation locations. Protein database files and python scripts are included for further investigation.",
author = "Benjamin Cocanougher and Umut Aypar and Amber McDonald and Linda Hasadsri and Bennett, {Michael J.} and Highsmith, {W Edward Jr.} and Kristin D'Aco",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.dib.2015.01.001",
language = "English (US)",
volume = "3",
pages = "34--39",
journal = "Data in Brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia

AU - Cocanougher, Benjamin

AU - Aypar, Umut

AU - McDonald, Amber

AU - Hasadsri, Linda

AU - Bennett, Michael J.

AU - Highsmith, W Edward Jr.

AU - D'Aco, Kristin

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Galactosemia is a metabolic disorder caused by mutations in the GALT gene [1,2]. We encountered a patient heterozygous for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]. Reminiscent of patients with the S135L mutation, our patient had loss of GALT enzyme activity in erythrocytes but a very mild clinical phenotype [3-8]. We performed splicing experiments and computational structural analyses to investigate the role of the novel S222N variant. Alamut software data predicted loss of splicing enhancers for the S222N and S135L mutations [9,10]. A cDNA library was generated from our patient's RNA to investigate for splicing errors, but no change in transcript length was seen [3]. In silico structural analysis was performed to investigate enzyme stability and attempt to understand the mechanism of the atypical galactosemia phenotype. Stability results are publicly available in the GALT Protein Database 2.0 [11-14]. Animations were created to give the reader a dynamic view of the enzyme structure and mutation locations. Protein database files and python scripts are included for further investigation.

AB - Galactosemia is a metabolic disorder caused by mutations in the GALT gene [1,2]. We encountered a patient heterozygous for a known pathogenic H132Q mutation and a novel S222N variant of unknown significance [3]. Reminiscent of patients with the S135L mutation, our patient had loss of GALT enzyme activity in erythrocytes but a very mild clinical phenotype [3-8]. We performed splicing experiments and computational structural analyses to investigate the role of the novel S222N variant. Alamut software data predicted loss of splicing enhancers for the S222N and S135L mutations [9,10]. A cDNA library was generated from our patient's RNA to investigate for splicing errors, but no change in transcript length was seen [3]. In silico structural analysis was performed to investigate enzyme stability and attempt to understand the mechanism of the atypical galactosemia phenotype. Stability results are publicly available in the GALT Protein Database 2.0 [11-14]. Animations were created to give the reader a dynamic view of the enzyme structure and mutation locations. Protein database files and python scripts are included for further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84923885202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923885202&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2015.01.001

DO - 10.1016/j.dib.2015.01.001

M3 - Article

AN - SCOPUS:84923885202

VL - 3

SP - 34

EP - 39

JO - Data in Brief

JF - Data in Brief

SN - 2352-3409

ER -